Skip to content
value.today

CytomX Therapeutics, Inc.

Total raised
$99 M
3 rounds on record
Latest round
$70 M
Jun 2015
First round on record
Jul 2012
Today
Went public
See the company page

CytomX Therapeutics, Inc. is listed today as CytomX Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CytomX Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$30 MPrivate placement after listing$10 to $50 million

CytomX Therapeutics, Inc.: Private sale, Jun 2023

Investors in this round

4 investors had bought by the notice of Aug 17, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for CytomX Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris Ogden · Executive Officer
  • Jeff Landau · Executive Officer
  • Lloyd Rowland · Executive Officer
  • Marcia Belvin · Executive Officer
  • Sean McCarthy · Executive Officer, Director
  • Wayne Chu · Executive Officer
  • Alan Ashworth · Director
  • Elaine Jones · Director
  • Halley Gilbert · Director
  • James Meyers · Director
  • Mani Mohindru · Director
  • Matthew Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean McCarthy, Chief Executive Officer. Newest notice filed Aug 17, 2023. Read the notice at the SEC.

optionsSEC
Jun 2015$70 MNo. 3$50 to $250 million

CytomX Therapeutics, Inc.: Raise no. 3, Jun 2015

Investors in this round

33 investors had bought by the notice of Jun 25, 2015: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for CytomX Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean McCarthy · Executive Officer, Director
  • Elaine V. Jones · Director
  • Frederick W. Gluck · Director
  • Hoyoung W. Huh · Director
  • Neil W. Exter · Director
  • Rachel V. Humphrey · Director
  • Tim W. Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean McCarthy, Ceo. Newest notice filed Jun 25, 2015. Read the notice at the SEC.

equitySEC
Dec 2014$17 MNo. 2$10 to $50 million

CytomX Therapeutics, Inc.: Raise no. 2, Dec 2014

Investors in this round

4 investors had bought by the notice of Jan 6, 2015: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for CytomX Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $30 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean McCarthy · Executive Officer, Director
  • Elaine V. Jones · Director
  • Frederick W. Gluck · Director
  • Hoyoung W. Huh · Director
  • Neil W. Exter · Director
  • Tim W. Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “An additional $3,499,999 is committed.”

Signed by Sean McCarthy, Ceo. Newest notice filed Jan 6, 2015. Read the notice at the SEC.

equitySEC
Jul 2012$13 MNo. 1$10 to $50 million

CytomX Therapeutics, Inc.: Raise no. 1, Jul 2012

Investors in this round

3 investors had bought by the notice of Aug 10, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for CytomX Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $26 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fletcher W. Payne · Executive Officer
  • Sean McCarthy · Executive Officer, Director
  • Charles W. Homcy · Director
  • Frederick W. Gluck · Director
  • Hoyoung W. Huh · Director
  • Neil W. Exter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean McCarthy, Ceo. Newest notice filed Aug 10, 2012. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CytomX Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2023

Products and services#

No products or services of CytomX Therapeutics, Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in CytomX Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Canaan IX L.P.Fund or asset managernot statednot statedHeld Series B-1 and C preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3
Canaan Partners IX LLCFund or asset managernot statednot statedHeld Series B-1 and C preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Largest shareholders today

Institutions holding CytomX Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CytomX Therapeutics, Inc.
NameRoleNamed in
Chris OgdenExecutive officerAug 2023
Jeff LandauExecutive officerAug 2023
Lloyd RowlandExecutive officerAug 2023
Marcia BelvinExecutive officerAug 2023
Sean McCarthyExecutive officerAug 2023
Wayne ChuExecutive officerAug 2023
Fletcher W. PayneExecutive officerAug 2012
Alan AshworthDirectorAug 2023
Elaine JonesDirectorAug 2023
Halley GilbertDirectorAug 2023
James MeyersDirectorAug 2023
Mani MohindruDirectorAug 2023
Matthew YoungDirectorAug 2023
Sean McCarthyDirectorAug 2023
Elaine V. JonesDirectorJun 2015
Frederick W. GluckDirectorJun 2015
Hoyoung W. HuhDirectorJun 2015
Neil W. ExterDirectorJun 2015
Rachel V. HumphreyDirectorJun 2015
Tim W. ShannonDirectorJun 2015
Charles W. HomcyDirectorAug 2012

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.